Loading…
Loading…
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for FITY and 80,000+ other tickers.
See exactly how FITY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for FITY and 80,000+ other tickers.
Fifty 1 Labs, Inc. is a Nevada-based holding company that has shifted its focus to biotechnology and telehealth, centering on peptide science for musculoskeletal health, recovery, and performance. The company utilizes AI-driven research and aims to develop a telehealth platform for personalized peptide therapies. Formerly involved in automotive finance, the company is now pursuing growth in the functional medicine and life sciences sectors.
Acquisition expands Fifty 1 Labs' portfolio with a five-product musculoskeletal recovery platform focused on injury recovery, rehabilitation, connective tissue support, joint health, and peptide-focused research VANCOUVER, BC / ACCESS Newswire / August 26, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY), an emerging biotechnology and health innovation company focused on peptide science, musculoskeletal health, sports performance, injury recovery, rehabilitation, and evidence-driven wellness, today announced that it has acquired a musculoskeletal recovery product line from MSK Signal, a Canadian Biotech Company. The acquired product line includes five key product concepts designed to support Fifty 1 Labs' growth strategy in the peptide and musculoskeletal health markets.
Model expected to include digital intake, clinician evaluation, prescription routing, monitoring coordination, and subscription-based patient support VANCOUVER, BC / ACCESS Newswire / August 7, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY) today provided an overview of its planned U.S. - focused telehealth peptide services platform. The Company intends to develop a patient-facing service model that complements its peptide science and commercialization strategy while remaining separate from investigational clinical-development programs.
Company outlines dual platform spanning peptide R&D, AI-enabled discovery, and planned U.S. telehealth peptide services VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY) (the "Company" or "Fifty 1 Labs") today announced that it is positioning itself as a peptide biotechnology and telehealth company focused on advancing peptide science, musculoskeletal ("MSK") health, recovery, and evidence-driven product innovation. The Company's emerging strategy integrates three complementary areas: peptide research and development, AI-enabled discovery workflows, and a planned U.S.-focused telehealth peptide services platform.
AI-Enabled Discovery and Clinical-Stage Development Target Injury Recovery, Performance, and Tissue Healing VANCOUVER, BC / ACCESS Newswire / April 15, 2026 / Fifty 1 Labs, Inc. (OTC:FITY), powered by its AI initiatives today announced the continued expansion of its biotechnology strategy focused on peptide products, peptide discovery, and clinical research for musculoskeletal ("MSK") health, recovery, and performance. Building on its transition into biotechnology and life sciences, the Company is advancing an integrated platform that combines peptide science, artificial intelligence-enabled discovery, and staged clinical development to address unmet needs across muscle, tendon, ligament, and bone conditions.
Company Retires 1,748,933 Series B Preferred Shares, Permanently Blocking Conversion into 612,126,550 Common Shares - Bought Back with Company Funds VANCOUVER, BC / ACCESS Newswire / April 14, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY), an AI-powered biotechnology company focused on peptide therapeutics, today announced the successful retirement of 1,748,933 shares of its Series B Preferred Stock. This strategic move, completed using the Company's own funds in direct collaboration with the shareholder, permanently removes the potential for approximately 612,126,550 common shares from entering the market.